Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Baxter
Boehringer Ingelheim
McKesson
Johnson and Johnson

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Litigation Details for Boston Scientific Corporation v. Johnson & Johnson Inc. (D. Del. 2007)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Boston Scientific Corporation v. Johnson & Johnson Inc. (D. Del. 2007)

Docket   Start Trial Date Filed 2007-05-25
Court District Court, D. Delaware Date Terminated 2010-01-20
Cause 28:2201 Declaratory Judgment Assigned To Sue Lewis Robinson
Jury Demand Both Referred To
Parties BOSTON SCIENTIFIC CORPORATION; BOSTON SCIENTIFIC SCIMED, INC.; CORDIS CORPORATION; JOHNSON & JOHNSON; JOHNSON & JOHNSON; WYETH
Patents 5,362,718; 5,854,207; 5,916,870; 5,948,428; 6,034,054; 6,048,964; 6,127,173; 6,197,051; 6,433,003; 6,492,106; 6,689,375; 6,939,376; 7,041,319; 9,040,039
Attorneys David T. Pritikin; John G. Day; Jon M. Spanbauer; Josy W. Ingersoll; Karen Elizabeth Keller; Lauren E. Maguire; Russell E. Cass; Steven J. Balick; Tiffany Geyer Lydon; William H. Baumgartner
Link to Docket External link to docket
Small Molecule Drugs cited in Boston Scientific Corporation v. Johnson & Johnson Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Boston Scientific Corporation v. Johnson & Johnson Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Boston Scientific Corporation v. Johnson & Johnson Inc. (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 282 ) References Clted U.S. PATBNT DOCUMEN'IS 5,362.718 A 11!1994 Skotoiclti et al. ............. 514!…Exhibit Descrigtion Page 1. U.S. Patent No. 7,223,286 AI 2. U.S. Patent No. 6,3 84,046 A20 3. Promus Instructfonsfor…) Unlted States Patent am Patem No.: US 7,223,286 B2 Wright et al. (45) Date of Patent: *May 29, 2007 …Continued) patent is extended or adjusted under 35 DOCm, lE U.S.C. 154(b) by 265 days. FOREIGN PATENT NTS DE…984 patent); 628-73, 724-740, 773. 801-839 (Cordis expert testimony regarding the '984 patent), the External link to document
0000-00-00 285 (A736-A746) at A742-A743); U.S. Patent Nos. 6,476,200 and 6,492,106 to Sabatini et al. 7. ln 1997, when…States Patent No. 7,223,2861 (the "'3286 patent"Z), claims 1-5 ofUnited States Patent No. …;7286 patent"), claims 1-5 of United States Patent No. 7,229,473 (the "'473 patent"… VI. THE '662 PATENT 47. U.S. Patent No. 7,300,662 ("the '662 patent"), co-owned by…and 17-25 of United States Patent No. 7,300,662 (the "'662 patent") against Plaintiffs/Counter-Defendants External link to document
0000-00-00 294 62), U.S. Patent No, 5,563,145 to Failli (attached as Ex. 63), and U.S. Patent No. 5,362,718 to Skotnicki…the ;7286 patent, ‘3286 patent, ‘473 patent, and U.S. Patent No. 7,300,662 (“the ’662 patent”), BSC’s …stent patents assigned to Medtronic. (See, e.g., Berg patent, Tuch patent, Wolft` patent). -32… Berg Patent in Combination With the Monis Patent, Further in View of the Skotnicki ’286 Patent ......…claims of U.S. Patent No. 7,217,286 (“the ‘7286 patent,” attached as Ex. 1)1, U.S. Patent No. 7,223,286 External link to document
0000-00-00 297 the in vivo effects of any such stent. (Id. at 6:34-54 (JA17)). The claimed stents simply are not the… claim of the ‘7286 patent, the ‘3286 patent, the ‘473 patent, and the ‘662 patent. BSC’s Promus® stent… four patents-in-suit, three of which - the ‘7286 patent, the ‘3286 patent, and the ‘473 patent - share… United States Patent Nos. 7,217,286 (“the ‘7286 patent”), 7,223,286 (“the ‘3286 patent”), 7,229,473 (…1997. These three patents are referred to herein as “the 1997 Patents.” The ‘662 patent was written about External link to document
0000-00-00 326 part 2 gt;f 35 United States Patent 1191 U3005362718A [11} _Patent Number: 5,362,718 …UNrrEi) sTATEs PATENT AND TRADEMARK oFFiCE CERTIFICATE OF CORRECTION PATENT NO. : 5,362,718 DATED : November…A1064 Case 1:07-cv-00333-SLR Document 326-1 5,362,718 Page 2 wherein Rl and R2 are each, independently…A1065 Case 1:07-cv-00333-SLR Document 326-1 5,362,718 1 RAPAM¥CIN HYDROXYESTERS BACKGROUND OF THE …A1066 Case 1:07-cv-00333-SLR Document 326-1 5,362,718 3 The pharmaceutically acceptable salts are External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Baxter
Moodys
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.